pre-IPO PHARMA

COMPANY OVERVIEW

Immunitas Therapeutics, founded by Longwood Fund, employs a single cell genomics platform to dissect the biology of immune cells in human tumors, thereby advancing discoveries directly from the bench into meaningful clinical improvements. Our focus on human data allows us to start with and stay closer to the biology that is most relevant in patients and greatly accelerates the pace of our research. The Immunitas team of scientific pioneers innovates around each step of the drug development process, first identifying novel targets, then designing therapeutic strategies, and developing key biomarkers to guide the selection of patients who may benefit from our new drugs.


LOCATION

  • Cambridge, MA, USA

  • THERAPEUTIC AREAS

  • Oncology

  • WEBSITE

    https://www.immunitastx.com


    CAREER WEBSITE

    https://www.immunitastx.com/#join-us


    SOCIAL MEDIA


    INVESTORS

    alexandria-venture-investments evotec leaps-by-bayer longwood-fund m-ventures novartis-venture-fund


    PRESS RELEASES


    Sep 21, 2022

    Immunitas Therapeutics Receives FDA Clearance of IND Application for IMT-009 in Solid Tumors and Hematological Malignancies


    Aug 18, 2021

    Immunitas Therapeutics Completes $58 Million Series B Financing to Advance Pipeline into the Clinic and Expand Single Cell Analysis Drug Development Platform for Immuno-Oncology and Other Diseases


    Feb 17, 2021

    Immunitas Therapeutics Announces Cell Publication of Tumor Single Cell Analysis Identifying CD161 as a Therapeutic T and NK Cell Target in Immuno-Oncology


    Dec 18, 2019

    Jeffrey Goldberg Appointed Chief Executive Officer and Director of Immunitas Therapeutics


    Nov 21, 2019

    Immunitas Therapeutics Launches with $39 Million to Advance Lead Programs to Human Efficacy Studies Based on a Unique Immunology-Focused Drug Development Platform


    For More Press Releases


    Google Analytics Alternative